Kaufman, H. L., Kohlhapp, F. J. & Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 14, 642–662 (2015).
Yu, X. & He, S. The interplay between human herpes simplex virus infection and the apoptosis and necroptosis cell death pathways. Virol. J. 13, 77 (2016).
Lin, E. & Nemunaitis, J. Oncolytic viral therapies. Cancer Gene Ther. 11, 643–664 (2004).
Raja, J. et al. Oncolytic virus immunotherapy: future prospects for oncology. J. Immunother. Cancer 6, 140 (2018).
Russell, S. J., Bell, J. C., Engeland, C. E. & McFadden, G. Advances in oncolytic virotherapy. Commun. Med 2, 33 (2022).
Aghi, M. & Martuza, R. L. Oncolytic viral therapies – the clinical experience. Oncogene 24, 7802–7816 (2005).
Seegers, S. L. et al. Experimental evolution generates novel oncolytic vesicular stomatitis viruses with improved replication in virus-resistant pancreatic cancer cells. J. Virol 94, e01643–19 (2020).
GMI. Oncolytic Virus Immunotherapy Market Size Report, 2023–2032, https://www.gminsights.com/industry-analysis/oncolytic-virus-immunotherapy-market (2024).
Replimune Group Inc. Replimune receives breakthrough therapy designation for RP1 and submits RP1 biologics license application to the FDA under the accelerated approval pathway, https://www.replimune.com (2024).
Feola, S., Russo, S., Ylosmaki, E. & Cerullo, V. Oncolytic ImmunoViroTherapy: a long history of crosstalk between viruses and immune system for cancer treatment. Pharmacol. Ther. 236, 108103 (2022).
Malfitano, A. M. et al. Viroth24, erapy: from single agents to combinatorial treatments. Biochem Pharm. 177, 113986 (2020).
Dock, G. The influence of complicating diseases upon leukaemia. Am. J. Med. Sci. 127, 563–592 (1904).
Southam, C. M. & Moore, A. E. Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer 5, 1025–1034 (1952).
Kelly, E. & Russell, S. J. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15, 651–659 (2007).
Moore, A. E. Effects of viruses on tumors. Annu. Rev. Microbiol. 8, 393–410 (1954).
Sinkovics, J. & Horvath, J. New developments in the virus therapy of cancer: a historical review. Intervirology 36, 193–214 (1993).
Anderson, W. F. Prospects for human gene therapy. Science 226, 401–409 (1984).
Martuza, R. L. et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854–856 (1991).
Todo, T. et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum. Gene Ther. 10, 2741–2755 (1999).
Fu, X. et al. Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells. Mol. Ther. 20, 339–346 (2012).
Jhawar, S. R. et al. Oncolytic viruses-natural and genetically engineered cancer immunotherapies. Front. Oncol. 7, 202 (2017).
Burke, J. M. et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J. Urol. 188, 2391–2397 (2012).
Rivadeneira, D. B. et al. Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T cell metabolism and promote tumor clearance. Immunity 51, 548–560 e544 (2019).
Park, A. K. et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci. Transl. Med. 12, eaaz1863 (2020).
Russell, T. A., Stefanovic, T. & Tscharke, D. C. Engineering herpes simplex viruses by infection-transfection methods including recombination site targeting by CRISPR/Cas9 nucleases. J. Virol. 213, 18–25 (2015).
Mahmood, M. et al. Revolutionizing personalized cancer treatment: the synergy of next-generation sequencing and CRISPR/Cas9. Per. Med. 21, 175–190 (2024).
Zhang, N. et al. Construction of an IL12 and CXCL11 armed oncolytic herpes simplex virus using the CRISPR/Cas9 system for colon cancer treatment. Virus Res. 323, 198979 (2023).
Alberts, P. et al. The advent of oncolytic virotherapy in oncology: the Rigvir(R) story. Eur. J. Pharmacol. 837, 117–126 (2018).
Yu, W. & Fang, H. Clinical trials with oncolytic adenovirus in China. Curr. Cancer Drug Targets 7, 141–148 (2007).
Liang, M. Oncorine, the world first oncolytic virus medicine and its update in China. Curr. Cancer Drug Targets 18, 171–176 (2018).
Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780–2788 (2015).
Todo, T. et al. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat. Med. 28, 1630–1639 (2022).
Sugawara, K. et al. Oncolytic herpes virus G47Delta works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation. Mol. Ther. Oncol. 22, 129–142 (2021).
Macedo, N., Miller, D. M., Haq, R. & Kaufman, H. L. Clinical landscape of oncolytic virus research in 2020. J. Immunother. Cancer. 8, e001486 (2020).
Malogolovkin, A. et al. Combinatorial approaches for cancer treatment using oncolytic viruses: projecting the perspectives through clinical trials outcomes. Viruses 13, 1271 (2021).
Ekrami, E., Ghanbari, P., Othman, E. M. & Szalay, A. A. The 16th international oncolytic virotherapy conference: from in vitro to clinical studies, novel approaches in cancer therapy meeting report. Front Immunol. 16, 1554767 (2025).
Vazquez, C. & Jurado, K. A. Neurotropic RNA Virus Modulation of Immune Responses within the Central Nervous System. Int. J. Mol. Sci. 23, 4018 (2022).
Barr, J. N. & Fearns, R. in Genome stability: From virus to human application (eds I. Kovalchuk & O. Kovalchuk) 21-35 (Academic Press, 2021).
Peters, C. & Rabkin, S. D. Designing herpes viruses as oncolytics. Mol. Ther. Oncolytics 2, 15010 (2015).
Dai, M. H. et al. Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. Br. J. Surg. 97, 1385–1394 (2010).
Eisenberg, D. P. et al. 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J. Gastrointest. Surg. 9, 1068–1077 (2005).
Liu, B. L. et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10, 292–303 (2003).
Sanchala, D. S., Bhatt, L. K. & Prabhavalkar, K. S. Oncolytic herpes simplex viral therapy: a stride toward selective targeting of cancer cells. Front. Pharmacol. 8, 270 (2017).
Aldrak, N. et al. Oncolytic herpes simplex virus-based therapies for cancer. Cells. 10, 1541 (2021).
Hartkopf, A. D., Fehm, T., Wallwiener, D. & Lauer, U. Oncolytic virotherapy of gynecologic malignancies. Gynecol. Oncol. 120, 302–310 (2011).
De Clercq, E. Antiviral drugs in current clinical use. J. Clin. Oncol. 30, 115–133 (2004).
Todo, T. “Armed” oncolytic herpes simplex viruses for brain tumor therapy. Cell Adh. Migr. 2, 208–213 (2008).
Sokolowski, N. A., Rizos, H. & Diefenbach, R. J. Oncolytic virotherapy using herpes simplex virus: how far have we come?. Oncolytic Virother. 4, 207–219 (2015).
Thomas, S. et al. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. J. Immunother. Cancer 7, 214 (2019).
Todo, T. Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front. Biosci. 13, 2060–2064 (2008).
Streby, K. A. et al. Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients. Clin. Cancer Res. 23, 3566–3574 (2017).
Ma, Y. et al. Inhibition of TANK binding kinase 1 by herpes simplex virus 1 facilitates productive infection. J. Virol. 86, 2188–2196 (2012).
Wang, J. N., Hu, P., Zeng, M. S. & Liu, R. B. Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma. Chin. J. Cancer 30, 831–841 (2011).
Russell, L. & Peng, K. W. The emerging role of oncolytic virus therapy against cancer. Chin. Clin. Oncol. 7, 16 (2018).
Masoud, S. J. et al. Efficacy of talimogene laherparepvec (T-VEC) therapy in patients with in-transit melanoma metastasis decreases with increasing lesion size. Ann. Surg. Oncol. 26, 4633–4641 (2019).
Johnson, D. B., Puzanov, I. & Kelley, M. C. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy 7, 611–619 (2015).
Sharma, D. et al. An insight into current treatment strategies, their limitations, and ongoing developments in vaccine technologies against herpes simplex infections. Vaccines 11, 206 (2023).
Andtbacka, R. H. et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM Phase III clinical trial. Ann. Surg. Oncol. 23, 4169–4177 (2016).
Zhang, T. et al. Talimogene Laherparepvec (T-VEC): a review of the recent advances in cancer therapy. J. Clin. Med. 12, 1098 (2023).
Kaufman, H. L., Shalhout, S. Z. & Iodice, G. Talimogene laherparepvec: moving from first-in-class to best-in-class. Front. Mol. Biosci. 9, 834841 (2022).
Trojaniello, C., Luke, J. J. & Ascierto, P. A. Therapeutic advancements across clinical stages in melanoma, with a focus on targeted immunotherapy. Front. Oncol. 11, 670726 (2021).
Senzer, N. N. et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 27, 5763–5771 (2009).
Todo, T., Martuza, R. L., Rabkin, S. D. & Johnson, P. A. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl Acad. Sci. USA 98, 6396–6401 (2001).
Fukuhara, H. et al. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin. Cancer Res. 11, 7886–7890 (2005).
Liu, R., Martuza, R. L. & Rabkin, S. D. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther. 12, 647–654 (2005).
Varghese, S. et al. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther. 13, 253–265 (2006).
Prabhakar, S. et al. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Ther. 14, 460–467 (2007).
Wang, J. et al. Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta. Cancer Cell Int 14, 83 (2014).
Antoszczyk, S. et al. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. Neuro. Oncol. 16, 1057–1066 (2014).
Wang, J. N. et al. Treatment of human thyroid carcinoma cells with the g47delta oncolytic herpes simplex virus. Asian Pac. J. Cancer Prev. 16, 1241–1245 (2015).
Cheema, T. A. et al. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc. Natl Acad. Sci. USA 110, 12006–12011 (2013).
Foreman, P. M., Friedman, G. K., Cassady, K. A. & Markert, J. M. Oncolytic virotherapy for the treatment of malignant glioma. Neurotherapeutics 14, 333–344 (2017).
Todo, T. et al. A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma. Nat. Commun. 13, 4119 (2022).
Kambara, H., Okano, H., Chiocca, E. A. & Saeki, Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. 65, 2832–2839 (2005).
Su, Y., Su, C. & Qin, L. Current landscape and perspective of oncolytic viruses and their combination therapies. Transl. Oncol. 25, 101530 (2022).
Kennedy, E. M. et al. Design of an interferon-resistant oncolytic HSV-1 incorporating redundant safety modalities for improved tolerability. Mol. Ther. Oncolytics 18, 476–490 (2020).
Chu, R. L., Post, D. E., Khuri, F. R. & Van Meir, E. G. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin. Cancer Res. 10, 5299–5312 (2004).
Bischoff, J. R. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373–376 (1996).
Nestić, D. et al. The revolving door of adenovirus cell entry: not all pathways are equal. Pharmaceutics 13, 1585 (2021).
Lee, C. H. et al. Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression. Biomaterials 35, 5505–5516 (2014).
Roelvink, P. W. et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol. 72, 7909–7915 (1998).
Charman, M., Herrmann, C. & Weitzman, M. D. Viral and cellular interactions during adenovirus DNA replication. FEBS Lett. 593, 3531–3550 (2019).
Huang, H. et al. Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy. Nat. Commun. 10, 4801 (2019).
Burleigh, K. et al. Human DNA-PK activates a STING-independent DNA sensing pathway. Sci. Immunol. 5, eaba4219 (2020).
Schaack, J. et al. E1A and E1B proteins inhibit inflammation induced by adenovirus. Proc. Natl. Acad. Sci. USA 101, 3124–3129 (2004).
Kitajima, S., Li, F. & Takahashi, C. Tumor milieu controlled by RB tumor suppressor. Int. J. Mol. Sci. 21, 2450 (2020).
Heise, C. et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6, 1134–1139 (2000).
Lang, F. F. et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J. Clin. Oncol. 36, 1419–1427 (2018).
Yamanaka, M. et al. E1B-55 kDa-defective adenoviruses activate p53 in mesothelioma and enhance cytotoxicity of anticancer agents. J. Thorac. Oncol. 7, 1850–1857 (2012).
Xia, Z. J. et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng 23, 1666–1670 (2004).
Pathak, V. et al. Molecular magnetic resonance imaging of Alpha-v-Beta-3 integrin expression in tumors with ultrasound microbubbles. Biomaterials 275, 120896 (2021).
Hensen, L. C. M., Hoeben, R. C. & Bots, S. T. F. Adenovirus receptor expression in cancer and its multifaceted role in oncolytic adenovirus therapy. Int. J. Mol. Sci. 21, 6828 (2020).
Matsunaga, W. & Gotoh, A. Adenovirus as a vector and oncolytic virus. Curr. Issues Mol. Biol. 45, 4826–4840 (2023).
Fares, J. et al. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. Lancet Oncol. 22, 1103–1114 (2021).
Kaliberov, S. A. et al. Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer. Mol. Ther. 10, 1059–1070 (2004).
Poulin, K. L., Clarkin, R. G., Del Papa, J. & Parks, R. J. Development and characterization of an oncolytic human adenovirus-based vector co-expressing the adenovirus death protein and p14 fusion-associated small transmembrane fusogenic protein. Int J Mol Sci. 25, 12451 (2024).
Gibson, H. et al. Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors. Oncoimmunology 4, e984523 (2015).
Akbulut, H. et al. A bicistronic adenoviral vector carrying cytosine deaminase and granulocyte-macrophage colony-stimulating factor increases the therapeutic efficacy of cancer gene therapy. Hum. Gene Ther. 30, 999–1007 (2019).
Hossain, J. A. et al. Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma. Neuro. Oncol. 21, 890–900 (2019).
Wang, P. et al. Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat. Commun. 8, 1395 (2017).
Xue, Q. et al. Efficacy of recombinant adenovirus expressing a fusion gene from GM-CSF and Epstein-Barr virus LMP2A in a mouse tumor model. Hum. Vaccin. Immunother. 13, 2260–2268 (2017).
Tang, C. et al. Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical. Clin. Transl. Oncol. 24, 1682–1701 (2022).
Koski, A. et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol. Ther. 18, 1874–1884 (2010).
Zafar, S. et al. CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. Oncoimmunology 7, e1490856 (2018).
Uchio, E. M. et al. A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG). J. Clin. Oncol. 40, TPS598–TPS598 (2022).
Ramesh, N. et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer. Clin. Cancer Res. 12, 305–313 (2006).
Javanbakht, M. et al. Oncolytic viruses: a novel treatment strategy for breast cancer. Genes Dis. 10, 430–446 (2023).
Havunen, R. et al. Cytokine-coding oncolytic adenovirus TILT-123 is safe, selective, and effective as a single agent and in combination with immune checkpoint inhibitor anti-PD-1. Cells. 10, 246 (2021).
Albarnaz, J. D. et al. Molecular mimicry of NF-kappaB by vaccinia virus protein enables selective inhibition of antiviral responses. Nat. Microbiol. 7, 154–168 (2022).
Moss, B. Poxvirus DNA replication. Cold Spring Harb. Perspect. Biol. 5, a010199 (2013).
Guo, Z. S. et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J. Immunother. Cancer 7, 6 (2019).
Li, M. et al. Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review. Cancer Biol. Med. 20, 646–661 (2023).
Hiley, C. T., Yuan, M., Lemoine, N. R. & Wang, Y. Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours. Gene Ther. 17, 281–287 (2010).
Asad, A. S. et al. Viral gene therapy for breast cancer: progress and challenges. Expert Opin. Biol. Ther. 17, 945–959 (2017).
Parato, K. A. et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol. Ther. 20, 749–758 (2012).
Mayor, J., Torriani, G., Rothenberger, S. & Engler, O. T-cell immunoglobulin and mucin (TIM) contributes to the infection of human airway epithelial cells by pseudotype viruses containing Hantaan virus glycoproteins. Virology 543, 54–62 (2020).
Moss, B. Poxvirus cell entry: how many proteins does it take? Viruses 4, 688–707 (2012).
Puhlmann, M. et al. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther. 7, 66–73 (2000).
Shi, Z. et al. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy. Biochem. Biophys. Res. Commun. 559, 176–182 (2021).
Foloppe, J. et al. The enhanced tumor specificity of TG6002, an armed oncolytic vaccinia virus deleted in two genes involved in nucleotide metabolism. Mol. Ther. Oncolytics 14, 1–14 (2019).
Vliegen, I. et al. Deletion of the vaccinia virus F13L gene results in a highly attenuated virus that mounts a protective immune response against subsequent vaccinia virus challenge. Antivir. Res. 93, 160–166 (2012).
Pelin, A. et al. Deletion of apoptosis inhibitor F1L in vaccinia virus increases safety and oncolysis for cancer therapy. Mol. Ther. Oncolytics. 14, 246–252 (2019).
Guse, K., Cerullo, V. & Hemminki, A. Oncolytic vaccinia virus for the treatment of cancer. Expert Opin. Biol. Ther. 11, 595–608 (2011).
Heo, J. et al. A phase II trial of JX-594, a targeted multimechanistic oncolytic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 30, e14566–e14566 (2012).
Abou-Alfa, G. K. et al. PHOCUS: a phase 3, randomized, open-label study of sequential treatment with Pexa-Vec (JX-594) and sorafenib in patients with advanced hepatocellular carcinoma. Liver Cancer 13, 248–264 (2024).
Fend, L. et al. Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment. Oncoimmunology 5, e1080414 (2016).
Delaunay, T. et al. High oncolytic activity of a double-deleted vaccinia virus copenhagen strain against malignant pleural mesothelioma. Mol. Ther. Oncolytics 18, 573–578 (2020).
Zhang, Q. et al. The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation. Mol. Genet. Genom. 282, 417–435 (2009).
Lauer, U. M. et al. Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis. Clin. Cancer Res. 24, 4388–4398 (2018).
Minev, B. R. et al. First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells. J. Transl. Med. 17, 271 (2019).
Kannanganat, S. et al. Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine. J. Immunol. 185, 7262–7273 (2010).
Zhang, B. & Cheng, P. Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy. Mol. Cancer 19, 158 (2020).
Chard, L. S. et al. A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer. Clin. Cancer Res. 21, 405–416 (2015).
Mirbahari, S. N. et al. Recent progress in combination therapy of oncolytic vaccinia virus. Front. Immunol. 15, 1272351 (2024).
Gong, J., Sachdev, E., Mita, A. C. & Mita, M. M. Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity. World J. Methodol. 6, 25–42 (2016).
Clements, D., Helson, E., Gujar, S. A. & Lee, P. W. Reovirus in cancer therapy: an evidence-based review. Oncolytic Virother. 3, 69–82 (2014).
Gong, J. & Mita, M. M. Activated ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells. Front. Oncol. 4, 167 (2014).
Morris, D. G. et al. REO-001: a phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin(R)) in patients with advanced solid tumors. Investig. N. Drugs 31, 696–706 (2013).
Jonker, D. J. et al. A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND.210, a Canadian Cancer Trials Group trial. Clin. Colorectal Cancer 17, 231–239 e237 (2018).
Cohn, D. E. et al. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin(R)) in recurrent ovarian, tubal, or peritoneal cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol. Oncol. 146, 477–483 (2017).
Bradbury, P. A. et al. Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. Lung Cancer 120, 142–148 (2018).
Noonan, A. M. et al. Randomized phase 2 trial of the oncolytic virus Pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma. Mol. Ther. 24, 1150–1158 (2016).
Bernstein, V. et al. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. Breast Cancer Res. Treat. 167, 485–493 (2018).
Mahalingam, D. et al. A phase II study of REOLYSIN((R)) (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. Cancer Chemother. Pharmacol. 79, 697–703 (2017).
Yun, C. O., Hong, J. & Yoon, A. R. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements. Front. Immunol. 13, 953410 (2022).
El-Sherbiny, Y. M. et al. Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo. Clin. Exp. Immunol. 180, 98–107 (2015).
Mahalingam, D. et al. Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: a phase Ib study. Clin. Cancer Res. 26, 71–81 (2020).
Samson, A. et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci. Transl. Med. 10, eaam7577 (2018).
Manso, L. et al. Abstract CT191: a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer (AWARE-1). Cancer Res. 81, CT191–CT191 (2021).
Seufferlein, T. et al. GOBLET study: results of the safety run-in for first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients treated with pelareorep + modified FOLFIRINOX +/- atezolizumab. J. Clin. Oncol. 43, 730–730 (2025).
Arnold, D. et al. 650 Pelareorep combined with atezolizumab and chemotherapy demonstrates encouraging results as first-line treatment in advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – interim results from the GOBLET study. J. Immunother. Cancer 10, A681–A681 (2022).
Fernandes, J. P. et al. Breast tumor-associated metalloproteases restrict reovirus oncolysis by cleaving the sigma1 cell attachment protein and can be overcome by mutation of sigma1. J. Virol. 93, e01380–19 (2019).
Liu, H. & Luo, H. Development of Group B coxsackievirus as an oncolytic virus: opportunities and challenges. Viruses. 13, 1082 (2021).
Kaufman, H. L., Kohlhapp, F. J. & Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 15, 660 (2016).
Shafren, D. R. et al. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin. Cancer Res. 10, 53–60 (2004).
Shafren, D. R. et al. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J. Virol. 71, 4736–4743 (1997).
Annels, N. E. et al. Oncolytic immunotherapy for bladder cancer using Coxsackie A21 virus. Mol. Ther. Oncolytics 9, 1–12 (2018).
Curti, B. et al. Abstract CT114: the MITCI (Phase 1b) study: a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy treatment. Cancer Res. 77, CT114–CT114 (2017).
Annels, N. E. et al. Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer. Clin. Cancer Res. 25, 5818–5831 (2019).
Curti, B. et al. 381 Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study. J. Immunother. Cancer 9, A415–A415 (2021).
Janmaat, M. L. et al. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int. J. Cancer 118, 209–214 (2006).
Guo, W. F. et al. Identification of differentially expressed genes contributing to radioresistance in lung cancer cells using microarray analysis. Radiat. Res. 164, 27–35 (2005).
Deng, H. et al. Coxsackievirus type B3 is a potent oncolytic virus against KRAS-mutant lung adenocarcinoma. Mol. Ther. Oncolytics 14, 266–278 (2019).
Reddy, P. S. et al. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J. Natl. Cancer Inst. 99, 1623–1633 (2007).
Schenk, E. L. et al. A randomized double-blind phase II study of the Seneca Valley virus (NTX-010) versus placebo for patients with extensive-stage SCLC (ES SCLC) who were stable or responding after at least four cycles of platinum-based chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study. J. Thorac. Oncol. 15, 110–119 (2020).
Rudin, C. M. et al. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin. Cancer Res. 17, 888–895 (2011).
Brown, M. C. et al. Oncolytic polio virotherapy of cancer. Cancer 120, 3277–3286 (2014).
Giotta Lucifero, A. & Luzzi, S. Against the resilience of high-grade gliomas: gene therapies (Part II). Brain Sci. 11, 976 (2021).
Bhattacharjee, S. & Yadava, P. K. Measles virus: background and oncolytic virotherapy. Biochem. Biophys. Rep. 13, 58–62 (2018).
Yang, H. et al. The application of Newcastle Disease Virus (NDV): vaccine vectors and tumor therapy. Viruses 16, 886 (2024).
Galanis, E. et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res. 75, 22–30 (2015).
Dispenzieri, A. et al. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia 31, 2791–2798 (2017).
Zhong, L. et al. Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. Cell 188, 1119–1136 e1123 (2025).
Wu, Q. et al. Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting. Int Immunopharmacol. 136, 112305 (2024).
Mansour, M., Palese, P. & Zamarin, D. Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J. Virol. 85, 6015–6023 (2011).
Kumar, R. et al. Role of MAPK/MNK1 signaling in virus replication. Virus Res. 253, 48–61 (2018).
Burton, C. & Bartee, E. Syncytia formation in oncolytic virotherapy. Mol. Ther. Oncolytics15, 131–139 (2019).
Higuchi, H. et al. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy. Cancer Res. 60, 6396–6402 (2000).
Sergel, T. A., McGinnes, L. W. & Morrison, T. G. A single amino acid change in the Newcastle disease virus fusion protein alters the requirement for HN protein in fusion. J. Virol. 74, 5101–5107 (2000).
Schirrmacher, V. Immunobiology of newcastle disease virus and its use for prophylactic vaccination in poultry and as adjuvant for therapeutic vaccination in cancer patients. Int. J. Mol. Sci. 18, 1103 (2017).
Garg, A. D. & Agostinis, P. Cell death and immunity in cancer: from danger signals to mimicry of pathogen defense responses. Immunol. Rev. 280, 126–148 (2017).
Keshavarz, M. et al. Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment. Virol. J. 17, 64 (2020).
Plitt, T. & Zamarin, D. Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations. Clin. Investig. 5, 75–87 (2015).
Meng, Q., He, J., Zhong, L. & Zhao, Y. Advances in the study of antitumour immunotherapy for newcastle disease virus. Int. J. Med. Sci. 18, 2294–2302 (2021).
Bai, F. L. et al. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. Cancer Biol. Ther. 15, 1226–1238 (2014).
Cuadrado-Castano, S. et al. Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models. Mol. Cancer Ther. 14, 1247–1258 (2015).
Wei, D. et al. Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice. J. Exp. Clin. Cancer Res. 34, 153 (2015).
Numpadit, S., Ito, C., Nakaya, T. & Hagiwara, K. Investigation of oncolytic effect of recombinant Newcastle disease virus in primary and metastatic oral melanoma. Med. Oncol. 40, 138 (2023).
Huang, F. et al. Development of molecular mechanisms and their application on oncolytic Newcastle disease virus in cancer therapy. Front. Mol. Biosci. 9, 889403 (2022).
Russell, S. J., Bell, J. C., Engeland, C. E. & McFadden, G. Advances in oncolytic virotherapy. Commun. Med. 2, 33 (2022).
Arnberg, N. Adenovirus receptors: implications for targeting of viral vectors. Trends Pharmacol. Sci. 33, 442–448 (2012).
Gao, J. et al. CD155, an onco-immunologic molecule in human tumors. Cancer Sci. 108, 1934–1938 (2017).
Kuryk, L. & Moller, A. W. Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor. J. Med. Virol. 92, 1309–1315 (2020).
Badrinath, N., Heo, J. & Yoo, S. Y. Viruses as nanomedicine for cancer. Int. J. Nanomed. 11, 4835–4847 (2016).
Farassati, F., Yang, A. D. & Lee, P. W. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell Biol. 3, 745–750 (2001).
Schmidt, F. I., Bleck, C. K. & Mercer, J. Poxvirus host cell entry. Curr. Opin. Virol. 2, 20–27 (2012).
Guo, Z. S., Thorne, S. H. & Bartlett, D. L. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim. Biophys. Acta 1785, 217–231 (2008).
Hindupur, S. V. et al. STAT3/5 inhibitors suppress proliferation in bladder cancer and enhance oncolytic adenovirus therapy. Int. J. Mol. Sci. 21, 1106 (2020).
McLaughlin, M. et al. The PERK inhibitor GSK2606414 enhances reovirus infection in head and neck squamous cell carcinoma via an ATF4-dependent mechanism. Mol. Ther. Oncolytics 16, 238–249 (2020).
Russell, L., Peng, K. W., Russell, S. J. & Diaz, R. M. Oncolytic viruses: priming time for cancer immunotherapy. BioDrugs 33, 485–501 (2019).
Schirrmacher, V. Molecular mechanisms of anti-neoplastic and immune stimulatory properties of oncolytic Newcastle disease virus. Biomedicines. 10, 562 (2022).
Cai, J. et al. Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1. Mol. Oncol. 14, 3153–3168 (2020).
Moskalev, A. V., Gumilevsky, B. Y., Zhestkov, A. V. & Zolotov, M. O. The effect of virus-induced cellular transformation on oncogenesis. Sci. Innov. Med. 8, 108–115 (2023).
Ariav, Y. et al. Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response. Sci Adv. 7, eabg6165 (2021).
Ramamurthy, N. et al. Evaluation of the oncolytic property of recombinant Newcastle disease virus strain R2B in 4T1 and B16-F10 cells in-vitro. Res. Vet. Sci. 139, 159–165 (2021).
Chiocca, E. A. & Rabkin, S. D. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol. Res. 2, 295–300 (2014).
Du, W., Na, J., Zhong, L. & Zhang, P. Advances in preclinical and clinical studies of oncolytic virus combination therapy. Front Oncol. 15, 1545542 (2025).
Mullen, J. T. & Tanabe, K. K. Viral oncolysis. Oncologist 7, 106–119 (2002).
Marcus, A. et al. Tumor-Derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response. Immunity 49, 754–763.e754 (2018).
Tian, Y., Xie, D. & Yang, L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct. Target. Ther. 7, 117 (2022).
Mantwill, K. et al. Concepts in oncolytic adenovirus therapy. Int. J. Mol. Sci. 22, 10522 (2021).
Wirth, T. et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res. 63, 3181–3188 (2003).
Takagi-Kimura, M. et al. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma. Cancer Sci. 104, 1433–1439 (2013).
Larrieux, A. & Sanjuan, R. Cellular resistance to an oncolytic virus is driven by chronic activation of innate immunity. iScience 26, 105749 (2023).
Baertsch, M. A. et al. MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus. Cancer Gene Ther. 21, 373–380 (2014).
Ruiz, A. J. & Russell, S. J. MicroRNAs and oncolytic viruses. Curr. Opin. Virol. 13, 40–48 (2015).
Yao, W. et al. The application of multiple miRNA response elements enables oncolytic adenoviruses to possess specificity to glioma cells. Virology 458-459, 69–82 (2014).
Luo, Q. et al. A triple-regulated oncolytic adenovirus carrying microRNA-143 exhibits potent antitumor efficacy in colorectal cancer. Mol. Ther. Oncolytics 16, 219–229 (2020).
Marzulli, M. et al. A novel oncolytic herpes simplex virus design based on the common overexpression of microRNA-21 in tumors. J. Gene Ther. 3, 8 (2018).
Chen, Y. et al. HSV-1-induced N6-methyladenosine reprogramming via ICP0-mediated suppression of METTL14 potentiates oncolytic activity in glioma. Cell Rep. 43, 114756 (2024).
Dai, W. et al. Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma. Nat. Commun. 15, 131 (2024).
Ju, F. et al. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade. J. Immunother. Cancer. 10, e004762 (2022).
Sivanandam, V. et al. Oncolytic viruses and immune checkpoint inhibition: the best of both worlds. Mol. Ther. Oncolytics 13, 93–106 (2019).
Packiriswamy, N. et al. Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma. Leukemia 34, 3310–3322 (2020).
Quixabeira, D. C. A. et al. Oncolytic adenovirus coding for a variant interleukin 2 (vIL-2) cytokine re-programs the tumor microenvironment and confers enhanced tumor control. Front. Immunol. 12, 674400 (2021).
Faghihkhorasani, A. et al. The role of oncolytic virotherapy and viral oncogenes in the cancer stem cells: a review of virus in cancer stem cells. Cancer Cell Int. 23, 250 (2023).
Wu, Y. Y. et al. Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response. Front. Cell. Infect. Microbiol. 13, 1142172 (2023).
Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and death. Nat. Immunol. 23, 487–500 (2022).
Mardi, A. et al. Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction. Cancer Cell Int. 22, 168 (2022).
Ahmed, A. & Tait, S. W. G. Targeting immunogenic cell death in cancer. Mol. Oncol. 14, 2994–3006 (2020).
Li, Z. et al. Immunogenic Cell Death activates the tumor immune microenvironment to boost the immunotherapy efficiency. Adv. Sci.9, e2201734 (2022).
Palanivelu, L., Liu, C. H. & Lin, L. T. Immunogenic cell death: the cornerstone of oncolytic viro-immunotherapy. Front. Immunol. 13, 1038226 (2022).
Imre, G. Cell death signalling in virus infection. Cell Signal 76, 109772 (2020).
Zhang, J., Chen, J. & Lin, K. Immunogenic cell death-based oncolytic virus therapy: a sharp sword of tumor immunotherapy. Eur. J. Pharmacol. 981, 176913 (2024).
Ladoire, S. et al. Cell-death-associated molecular patterns as determinants of cancer immunogenicity. Antioxid. Redox Signal. 20, 1098–1116 (2014).
Li, Q. et al. The gamble between oncolytic virus therapy and IFN. Front. Immunol. 13, 971674 (2022).
Galluzzi, L. et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J. Immunother. Cancer. 8, e00337 (2020).
Fucikova, J. et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 11, 1013 (2020).
Oh, J. H. et al. Sustained type I interferon reinforces NK cell-mediated cancer immunosurveillance during chronic virus infect246, ion. Cancer Immunol. Res. 7, 584–599 (2019).
Saha, D., Wakimoto, H. & Rabkin, S. D. Oncolytic herpes simplex virus interactions with the host immune system. Curr. Opin. Virol. 21, 26–34 (2016).
Johnson, E., Salari, K. & Yang, S. SETDB1: A perspective into immune cell function and cancer immunotherapy. Immunology 169, 3–12 (2023).
Bommareddy, P. K., Shettigar, M. & Kaufman, H. L. Integrating oncolytic viruses in combination cancer immunotherapy. Nat. Rev. Immunol. 18, 498–513 (2018).
Gujar, S., Bell, J. & Diallo, J. S. SnapShot: cancer immunotherapy with oncolytic viruses. Cell 176, 1240–1240.e1241 (2019).
Svensson-Arvelund, J. et al. Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity. Nat. Commun. 13, 7149 (2022).
Shi, T. et al. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment. Front. Immunol. 11, 683 (2020).
Cueto, F. J. et al. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells. J. Immunother. Cancer. 9, e002054 (2021).
Henke, E., Nandigama, R. & Ergun, S. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front. Mol. Biosci. 6, 160 (2019).
Lei, X. et al. CD4(+) T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors. Cell Mol. Immunol. 21, 374–392 (2024).
Chen, L. et al. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation. Theranostics 11, 6668–6681 (2021).
Cook, M. & Chauhan, A. Clinical application of oncolytic viruses: a systematic review. Int. J. Mol. Sci. 21, 7505 (2020).
Vesely, M. D., Kershaw, M. H., Schreiber, R. D. & Smyth, M. J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235–271 (2011).
Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017).
DePeaux, K. et al. An oncolytic virus-delivered TGFbeta inhibitor overcomes the immunosuppressive tumor microenvironment. J. Exp. Med. 220, e20230053 (2023).
Wang, L., Chard Dunmall, L. S., Cheng, Z. & Wang, Y. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment. J. Immunother. Cancer 10, e004167 (2022).
Nguyen, H. M., Guz-Montgomery, K. & Saha, D. Oncolytic virus encoding a master pro-inflammatory cytokine interleukin 12 in cancer immunotherapy. Cells 9, 400 (2020).
Ma, J. et al. Characterization of virus-mediate270, d immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer. Cell Death Dis. 11, 48 (2020).
Uche, I. K., Kousoulas, K. G. & Rider, P. J. F. The effect of herpes simplex virus-type-1 (HSV-1) oncolytic immunotherapy on the tumor microenvironment. Viruses 13, 1200 (2021).
Yamashita, M. et al. Oncolytic vaccinia virus induces a novel phenotype of CD8(+) effector T cells characterized by high ICOS expression. Mol. Ther. Oncolytics 20, 422–432 (2021).
Liu, Y. et al. Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade. Cell Death Dis. 11, 1062 (2020).
Hong, I. S. Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types. Exp. Mol. Med. 48, e242 (2016).
Robinson, M. et al. Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors. J. Virol. 83, 3450–3462 (2009).
Grossardt, C. et al. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum. Gene Ther. 24, 644–654 (2013).
Lemay, C. G. et al. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol. Ther. 20, 1791–1799 (2012).
Lee, J. H. et al. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther. 17, 73–79 (2010).
Pol, J., Kroemer, G. & Galluzzi, L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology 5, e1115641 (2016).
Ozga, A. J., Chow, M. T. & Luster, A. D. Chemokines and the immune response to cancer. Immunity 54, 859–874 (2021).
Liu, Z. et al. CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. Oncoimmunology 5, e1091554 (2016).
Moon, E. K. et al. Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. Oncoimmunology 7, e1395997 (2018).
Eckert, E. C. et al. Generation of a tumor-specific chemokine gradient using oncolytic vesicular stomatitis virus encoding CXCL9. Mol. Ther. Oncolytics 16, 63–74 (2020).
Pol, J. G. et al. Effects of interleukin-2 in immunostimulation and immunosuppression. J. Exp. Med. 217, e2019247 (2020).
Alva, A. et al. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol. Immunother. 65, 1533–1544 (2016).
Leoni, V. et al. A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors. PLoS Pathog. 14, e1007209 (2018).
Ansardamavandi, A. & Tafazzoli-Shadpour, M. The functional cross talk between cancer cells and cancer associated fibroblasts from a cancer mechanics perspective. Biochim. Biophys. Acta Mol. Cell Res. 1868, 119103 (2021).
Yamauchi, M. et al. Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer. Matrix Biol. 91-92, 8–18 (2020).
Everts, A., Bergeman, M., McFadden, G. & Kemp, V. Simultaneous tumor and stroma targeting by oncolytic viruses. Biomedicines 8, 474 (2020).
Barrett, R. L. & Pure, E. Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy. Elife 9, e57243 (2020).
Hosein, A. N., Brekken, R. A. & Maitra, A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat. Rev. Gastroenterol. Hepatol. 17, 487–505 (2020).
Biffi, G. & Tuveson, D. A. Diversity and biology of cancer-associated fibroblasts. Physiol. Rev. 101, 147–176 (2021).
Qin, Y. et al. Cancer-associated fibroblasts in gastric cancer affect malignant progression via the CXCL12-CXCR4 axis. J. Cancer 12, 3011–3023 (2021).
Aronovich, A. et al. Cancer-associated fibroblasts in mycosis fungoides promote tumor cell migration and drug resistance through CXCL12/CXCR4. J. Investig. Dermatol. 141, 619–627 e612 (2021).
Tong, Y. et al. Tumor-secreted exosomal lncRNA POU3F3 promotes cisplatin resistance in ESCC by Inducing fibroblast differentiation into CAFs. Mol. Ther. Oncolytics 18, 1–13 (2020).
Liu, T. et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J. Hematol. Oncol. 12, 86 (2019).
Kennel, K. B., Bozlar, M., De Valk, A. F. & Greten, F. R. Cancer-associated fibroblasts in inflammation and antitumor immunity. Clin. Cancer Res. 29, 1009–1016 (2023).
Ilkow, C. S. et al. Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nat. Med. 21, 530–536 (2015).
Hamad, A. et al. Recent developments in glioblastoma therapy: oncolytic viruses and emerging future strategies. Viruses. 15, 547 (2023).
Kiyokawa, J. et al. Modification of extracellular matrix enhances oncolytic adenovirus immunotherapy in glioblastoma. Clin. Cancer Res. 27, 889–902 (2021).
de Sostoa, J. et al. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager. J. Immunother. Cancer 7, 19 (2019).
Sette, P. et al. GBM-Targeted oHSV armed with matrix metalloproteinase 9 enhances anti-tumor activity and animal survival. Mol. Ther. Oncolytics15, 214–222 (2019).
Li, M. et al. Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Acta Neuropathol. Commun. 8, 221 (2020).
Afshar, K. et al. An overview of extracellular matrix and its remodeling in the development of cancer and metastasis with a glance at therapeutic approaches. Cell Biochem. Funct. 41, 930–952 (2023).
Browne, A. T., Clements, M., Ju, W. & Kaplan, R. Abstract 4273: Genetically engineered mesenchymal stromal cells degrade hyaluronic acid to disrupt the ECM and enhance cancer therapy outcomes. Cancer Res. 84, 4273–4273 (2024).
Wang, S. et al. An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy. J. Immunother. Cancer. 12, e008431 (2024).
Na, Y. et al. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model. J. Control Release 220, 766–782 (2015).
Tedcastle, A. et al. Actin-resistant DNAse I expression from oncolytic adenovirus enadenotucirev enhances its intratumoral spread and reduces tumor growth. Mol. Ther. 24, 796–804 (2016).
Jung, B. K. et al. Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade. J. Immunother. Cancer. 8, e000763 (2020).
Soko, G. F. et al. Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses. Front. Immunol. 15, 1535647 (2025).
Lugano, R., Ramachandran, M. & Dimberg, A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell. Mol. Life Sci. 77, 1745–1770 (2020).
Santry, L. A. et al. Tumour vasculature: Friend or foe of oncolytic viruses?. Cytokine Growth Factor Rev. 56, 69–82 (2020).
Babar, Q. et al. Targeting the tumor microenvironment: potential strategy for cancer therapeutics. Biochim. Biophys. Acta Mol. Basis Dis. 1869, 166746 (2023).
Closset, L. et al. The extracellular matrix – immune microenvironment crosstalk in cancer therapy: challenges and opportunities. Matrix Biol. 121, 217–228 (2023).
Arulanandam, R. et al. VEGF-mediated induction of PRD1-BF1/Blimp1 expression sensitizes tumor vasculature to oncolytic virus infection. Cancer Cell 28, 210–224 (2015).
Manocha, E. et al. Avian Reovirus P17 suppresses angiogenesis by promoting DPP4 secretion. Cells. 10, 259 (2021).
Lu, M. et al. Oncolytic virus as a novel modality for the treatment of prostate cancer. Discov. Med. 32, 133–139 (2021).
Zhou, D., Zhang, C., Sun, J. & Yuan, M. Neutrophils in oncolytic virus immunotherapy. Front. Immunol. 15, 1490414 (2024).
Breitbach, C. J. et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res. 73, 1265–1275 (2013).
Wang, J. Y. et al. Immunotherapy combining tumor and endothelium cell lysis with immune enforcement by recombinant MIP-3alpha Newcastle disease virus in a vessel-targeting liposome enhances antitumor immunity. J Immunother Cancer. 10, e003950 (2022).
Tysome, J. R. et al. Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther. 16, 1223–1233 (2009).
Mullen, J. T. et al. Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Cancer 101, 869–877 (2004).
Abou Khouzam, R. et al. Tumor hypoxia regulates immune escape/invasion: influence on angiogenesis and potential impact of hypoxic biomarkers on cancer therapies. Front. Immunol. 11, 613114 (2020).
Clarke, H. J., Chambers, J. E., Liniker, E. & Marciniak, S. J. Endoplasmic reticulum stress in malignancy. Cancer Cell 25, 563–573 (2014).
Lan, Q. et al. Development of oncolytic virotherapy: from genetic modification to combination therapy. Front. Med. 14, 160–184 (2020).
Xiao, T. et al. VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis. Cell Res. 20, 367–378 (2010).
Frentzen, A. et al. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc. Natl Acad. Sci. USA 106, 12915–12920 (2009).
Fukuhara, H., Ino, Y. & Todo, T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 107, 1373–1379 (2016).
Chen, L., Zuo, M., Zhou, Q. & Wang, Y. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects. Front. Immunol. 14, 1308890 (2023).
Nguyen, H. M., Bommareddy, P. K., Silk, A. W. & Saha, D. Optimal timing of PD-1 blockade in combination with oncolytic virus therapy. Semin. Cancer Biol. 86, 971–980 (2022).
Hemminki, O., Dos Santos, J. M. & Hemminki, A. Oncolytic viruses for cancer immunotherapy. J. Hematol. Oncol. 13, 84 (2020).
Chauvin, J. M. et al. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J. Clin. Investig. 125, 2046–2058 (2015).
Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651–668 (2020).
Buchbinder, E. I. & Desai, A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol. 39, 98–106 (2016).
Lee, W. S., Yang, H., Chon, H. J. & Kim, C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp. Mol. Med. 52, 1475–1485 (2020).
Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).
Patnaik, A. et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin. Cancer Res. 21, 4286–4293 (2015).
Topalian, S. L. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020–1030 (2014).
Jacquelot, N. et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat. Commun. 8, 592 (2017).
Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723 (2017).
Martini, V. et al. Oncolytic virotherapy: new weapon for breast cancer treatment. Ecancermedicalscience 14, 1149 (2020).
Ylosmaki, E. & Cerullo, V. Design and application of oncolytic viruses for cancer immunotherapy. Curr. Opin. Biotechnol. 65, 25–36 (2020).
Chow, A., Perica, K., Klebanoff, C. A. & Wolchok, J. D. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 19, 775–790 (2022).
Seyed-Khorrami, S. M. et al. A promising future in cancer immunotherapy: oncolytic viruses. Eur. J. Pharmacol. 960, 176063 (2023).
Zhang, H. et al. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model. Cancer Gene Ther. 29, 456–465 (2022).
Kelly, K. R. et al. Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia 32, 230–233 (2018).
Nassiri, F. et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat. Med. 29, 1370–1378 (2023).
Kontermann, R. E., Ungerechts, G. & Nettelbeck, D. M. Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics. MAbs 13, 1982447 (2021).
Li, R. et al. 666 Phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG). J. Immunother. Cancer 10, A696–A696 (2022).
Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109–1119.e1110 (2017).
Puzanov, I. et al. Talimogene Laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J. Clin. Oncol. 34, 2619–2626 (2016).
Chesney, J. et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J. Clin. Oncol. 36, 1658–1667 (2018).
Kelly, C. M. et al. Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial. JAMA Oncol. 6, 402–408 (2020).
Monaco, M. L., Idris, O. A. & Essani, K. Triple-negative breast cancer: basic biology and immuno-oncolytic viruses. Cancers 15, 2393 (2023).
Bourgeois-Daigneault, M. C. et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci. Transl. Med. 10, eaao1641 (2018).
Chesney, J. A. et al. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J. Clin. Oncol. 41, 528–540 (2023).
Li, S. J. & Sun, Z. J. Fueling immune checkpoint blockade with oncolytic viruses: current paradigms and challenges ahead. Cancer Lett. 550, 215937 (2022).
Zhou, P. et al. Intratumoral delivery of a novel oncolytic adenovirus encoding human antibody against PD-1 elicits enhanced antitumor efficacy. Mol. Ther. Oncolytics 25, 236–248 (2022).
Upadhaya, S. et al. Combinations take centre stage in PD1/PDL1 inhibitor clinical trials. Nat. Rev. Drug Discov. 20, 168–169 (2021).
Kirtane, K., Elmariah, H., Chung, C. H. & Abate-Daga, D. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J. Immunother. Cancer. 9, e002723 (2021).
Laskowski, T. & Rezvani, K. Adoptive cell therapy: living drugs against cancer. J. Exp. Med. 217, e20200377 (2020).
Perez, C. et al. Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts. Int. J. Cancer 137, 359–371 (2015).
Ellis, G. I., Sheppard, N. C. & Riley, J. L. Genetic engineering of T cells for immunotherapy. Nat. Rev. Genet. 22, 427–447 (2021).
Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74–80 (2015).
Li, J. et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol. Ther. 19, 650–657 (2011).
Nishio, N. & Dotti, G. Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors. Oncoimmunology 4, e988098 (2015).
Trujillo, J. A., Sweis, R. F., Bao, R. & Luke, J. J. T cell-inflamed versus non-T cell-inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection. Cancer Immunol. Res. 6, 990–1000 (2018).
Ajina, A. & Maher, J. Prospects for combined use of oncolytic viruses and CAR T-cells. J. Immunother. Cancer 5, 90 (2017).
Huang, J. et al. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma. Cancer Immunol. Immunother. 70, 2453–2465 (2021).
Jiang, H. et al. Adjuvant therapy with oncolytic adenovirus delta-24-RGDOX after intratumoral adoptive T-cell therapy promotes antigen spread to sustain systemic antitumor immunity. Cancer Res. Commun. 3, 1118–1131 (2023).
Feist, M. et al. Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy. Cancer Gene Ther. 28, 98–111 (2021).
Dagher, O., King, T. R., Wellhausen, N. & Posey, A. D. Jr. Combination therapy for solid tumors: taking a classic CAR on new adventures. Cancer Cell 38, 621–623 (2020).
Wing, A. et al. Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager. Cancer Immunol. Res. 6, 605–616 (2018).
Porter, C. E. et al. Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors. Mol. Ther. 28, 1251–1262 (2020).
Daei Sorkhabi, A. et al. The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies. Front. Immunol. 14, 1113882 (2023).
Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197–218 (2019).
Abate-Daga, D. et al. Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood 122, 1399–1410 (2013).
John, L. B., Kershaw, M. H. & Darcy, P. K. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology 2, e26286 (2013).
Ping, Y. et al. Augmenting the effectiveness of CAR-T cells by enhanced self-delivery of PD-1-neutralizing scFv. Front. Cell Dev. Biol. 8, 803 (2020).
Tanoue, K. et al. Armed oncolytic adenovirus-expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors. Cancer Res 77, 2040–2051 (2017).
Zheng, N. et al. Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance. Cancer Cell 40, 973–985.e977 (2022).
Mahasa, K. J., Ouifki, R., Eladdadi, A. & Pillis, L. A combination therapy of oncolytic viruses and chimeric antigen receptor T cells: a mathematical model proof-of-concept. Math. Biosci. Eng. 19, 4429–4457 (2022).
Watanabe, N., McKenna, M. K., Rosewell Shaw, A. & Suzuki, M. Clinical CAR-T cell and oncolytic virotherapy for cancer treatment. Mol. Ther. 29, 505–520 (2021).
Ran, G. H. et al. Natural killer cell homing and trafficking in tissues and tumors: from biology to application. Signal Transduct. Target. Ther. 7, 205 (2022).
Heipertz, E. L. et al. Current perspectives on “off-the-shelf” allogeneic NK and CAR-NK cell therapies. Front. Immunol. 12, 732135 (2021).
Li, F. et al. CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency. J. Immunother. Cancer. 8, (2020).
Ma, R. et al. An oncolytic virus expressing IL15/IL15Ralpha combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma. Cancer Res. 81, 3635–3648 (2021).
Liu, E. et al. Use of CAR-Transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545–553 (2020).
Nikolova, E., Tonev, D., Zhelev, N. & Neychev, V. Prospects for radiopharmaceuticals as effective and safe therapeutics in oncology and challenges of tumor resistance to radiotherapy. Dose Response 19, 1559325821993665 (2021).
Kumari, S. et al. Immunomodulatory effects of radiotherapy. Int. J. Mol. Sci. 21, 8151 (2020).
Ottolino-Perry, K. et al. Intelligent design: combination therapy with oncolytic viruses. Mol. Ther. 18, 251–263 (2010).
Markert, J. M. et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol. Ther. 22, 1048–1055 (2014).
Bieler, A. et al. Impact of radiation therapy on the oncolytic adenovirus dl520: implications on the treatment of glioblastoma. Radiother. Oncol. 86, 419–427 (2008).
Jayalie, V. F. & Sekarutami, S. M. Combining oncolytic virus and radiation therapy for cancer management. J. Cancer Metastasis Treat. 8, 17 (2022).
Kim, S. H. et al. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck. Eur. J. Cancer 41, 313–322 (2005).
Egami, T. et al. Radiation enhances adenoviral gene therapy in pancreatic cancer via activation of cytomegalovirus promoter and increased adenovirus uptake. Clin. Cancer Res. 14, 1859–1867 (2008).
Gao, H. et al. Synergistic suppression effect on tumor growth of colorectal cancer by combining radiotherapy with a TRAIL-armed oncolytic adenovirus. Technol. Cancer Res. Treat. 18, 1533033819853290 (2019).
Chen, W. Y. et al. Stereotactic body radiation combined with oncolytic vaccinia virus induces potent anti-tumor effect by triggering tumor cell necroptosis and DAMPs. Cancer Lett. 523, 149–161 (2021).
O’Cathail, S. M. et al. Combining oncolytic adenovirus with radiation-a paradigm for the future of radiosensitization. Front. Oncol. 7, 153 (2017).
Goff, P. H., Vijayakumar, G. & Palese, P. Oncolytic Newcastle disease virus expressing a checkpoint-inhibiting antibody as a radiosensitizing immunotherapy in a murine melanoma model. Int. J. Radiat. Oncol. Biol. Phys. 105, E648–E649 (2019).
Yan, Z. et al. Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments. Cancer Cell Int. 24, 242 (2024).
Gallego Perez-Larraya, J. et al. Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma. N. Engl. J. Med. 386, 2471–2481 (2022).
Shirakawa, Y. et al. Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments. Eur. J. Cancer 153, 98–108 (2021).
Chen, Y. et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res. 61, 5453–5460 (2001).
Mell, L. K. et al. Phase I trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma. Clin. Cancer Res. 23, 5696–5702 (2017).
Li, H. et al. HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy. Cancer Gene Ther. 20, 478–485 (2013).
Opyrchal, M. et al. Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS). Hum. Gene Ther. 23, 419–427 (2012).
Heinhuis, K. M. et al. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann. Oncol. 30, 219–235 (2019).
Lu, S. Y. et al. Microorganisms in chemotherapy for pancreatic cancer: an overview of current research and future directions. Int. J. Mol. Sci. 17, 2666–2682 (2021).
Jung, K. H. et al. Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer. Cancer Lett. 396, 155–166 (2017).
Workenhe, S. T. et al. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy. Cancer Immunol. Res. 1, 309–319 (2013).
Cerullo, V. et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol. Ther. 19, 1737–1746 (2011).
Khuri, F. R. et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879–885 (2000).
Song, X. et al. Combined treatment with an oncolytic adenovirus and antitumor activity of vincristine against retinoblastoma cells. Int. J. Mol. Sci. 13, 10736–10749 (2012).
Lee, J. C. et al. Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trial. Gastrointest. Endosc. 92, 1044–1052.e1041 (2020).
Kennedy, E. M. et al. Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer. Nat. Commun. 13, 5907 (2022).
Chattopadhyay, S. et al. A review exploring the fusion of oncolytic viruses and cancer immunotherapy: an innovative strategy in the realm of cancer treatment. Biochim. Biophys. Acta Rev. Cancer 1879, 189110 (2024).
Simpson, G. R. et al. Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. Oncolytic Virother. 5, 1–13 (2016).
Feinberg, A. P., Koldobskiy, M. A. & Gondor, A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 17, 284–299 (2016).
Li, G., Tian, Y. & Zhu, W. G. The roles of histone deacetylases and their inhibitors in cancer therapy. Front. Cell Dev. Biol. 8, 576946 (2020).
Li, Y. & Seto, E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb. Perspect. Med. 6, a026831 (2016).
Holdgate, G. A. et al. Drug discovery for epigenetics targets. Drug Discov. Today 27, 1088–1098 (2022).
Nusinzon, I. & Horvath, C. M. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc. Natl Acad. Sci. USA 100, 14742–14747 (2003).
Tang, X. et al. Acetylation-dependent signal transduction for type I interferon receptor. Cell 131, 93–105 (2007).
Nguyen, T. L. et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl Acad. Sci. USA 105, 14981–14986 (2008).
Marchini, A., Scott, E. M. & Rommelaere, J. Overcoming barriers in oncolytic virotherapy with HDAC inhibitors and immune checkpoint blockade. Viruses. 8, 9 (2016).
Vlasakova, J. et al. Histone deacetylase inhibitors suppress IFNalpha-induced up-regulation of promyelocytic leukemia protein. Blood 109, 1373–1380 (2007).
Chang, H. M. et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc. Natl Acad. Sci. USA 101, 9578–9583 (2004).
Wunder, T. et al. Expression of the coxsackie adenovirus receptor in neuroendocrine lung cancers and its implications for oncolytic adenoviral infection. Cancer Gene Ther. 20, 25–32 (2013).
Watanabe, T. et al. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp. Cell Res. 312, 256–265 (2006).
Otsuki, A. et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol. Ther. 16, 1546–1555 (2008).
Conte, M., De Palma, R. & Altucci, L. HDAC inhibitors as epigenetic regulators for cancer immunotherapy. Int. J. Biochem. Cell Biol. 98, 65–74 (2018).
Jennings, V. A. et al. Potentiating oncolytic virus-induced immune-mediated tumor cell killing using histone deacetylase inhibition. Mol. Ther. 27, 1139–1152 (2019).
Dion, L. D. et al. Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase. Virology 231, 201–209 (1997).
Sultan, M. H. et al. Epigenetic modulation by oncolytic viruses: Implications for cancer therapeutic efficacy. Biochim. Biophys. Acta Rev. Cancer 1880, 189270 (2025).
Murphy, S. A., Mapes, N. J. Jr., Dua, D. & Kaur, B. Histone modifiers at the crossroads of oncolytic and oncogenic viruses. Mol. Ther. 30, 2153–2162 (2022).
Shulak, L. et al. Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-kappaB-dependent autophagy. J. Virol. 88, 2927–2940 (2014).
Kapoor, P. et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 114, 518–521 (2009).
Wang, Y.-Y. et al. Dual-responsive epigenetic inhibitor nanoprodrug combined with oncolytic virus synergistically boost cancer immunotherapy by igniting gasdermin E-mediated pyroptosis. ACS Nano 18, 20167–20180 (2024).
Kaufman, H. L. & Bommareddy, P. K. Two roads for oncolytic immunotherapy development. J. Immunother. Cancer 7, 26 (2019).
Wang, J. et al. Localized delivery of immunotherapeutics: a rising trend in the field. J. Control Release 340, 149–167 (2021).
Wang, J. et al. Anti-tumor synergistic effect of a dual cancer-specific recombinant adenovirus and paclitaxel on breast cancer. Front. Oncol. 10, 244 (2020).
Bazan-Peregrino, M. et al. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. J. Immunother. Cancer. 9, e003254 (2021).
Lin, D., Shen, Y. & Liang, T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct. Target. Ther. 8, 156 (2023).
De Lombaerde, E., De Wever, O. & De Geest, B. G. Delivery routes matter: Safety and efficacy of intratumoral immunotherapy. Biochim Biophys. Acta Rev. Cancer 1875, 188526 (2021).
Rosenblum, D. et al. Progress and challenges towards targeted delivery of cancer therapeutics. Nat. Commun. 9, 1410 (2018).
Shaha, S., Rodrigues, D. & Mitragotri, S. Locoregional drug delivery for cancer therapy: Preclinical progress and clinical translation. J. Control Release 367, 737–767 (2024).
Moehler, M. et al. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology 8, 1615817 (2019).
Shalhout, S. Z., Miller, D. M., Emerick, K. S. & Kaufman, H. L. Therapy with oncolytic viruses: progress and challenges. Nat. Rev. Clin. Oncol. 20, 160–177 (2023).
Li, L. et al. Delivery and biosafety of oncolytic virotherapy. Front. Oncol. 10, 475 (2020).
Yoon, A. R. et al. Mesenchymal stem cell-mediated delivery of an oncolytic adenovirus enhances antitumor efficacy in hepatocellular carcinoma. Cancer Res. 79, 4503–4514 (2019).
Hammad, M. et al. Neural stem cells improve the delivery of oncolytic chimeric orthopoxvirus in a metastatic ovarian cancer model. Mol. Ther. Oncolytics18, 326–334 (2020).
Burke, B. et al. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am. J. Pathol. 163, 1233–1243 (2003).
Keshavarz, M. et al. Oncolytic virus delivery modulated immune responses toward cancer therapy: challenges and perspectives. Int. Immunopharmacol. 108, 108882 (2022).
Chen, Y. et al. An oncolytic virus-T cell chimera for cancer immunotherapy. Nat. Biotechnol. 42, 1876–1887 (2024).
Atasheva, S. et al. Systemic cancer therapy with engineered adenovirus that evades innate immunity. Sci. Transl. Med. 12, eabc6659 (2020).
Lv, P. et al. Genetically engineered cell membrane nanovesicles for oncolytic adenovirus delivery: a versatile platform for cancer virotherapy. Nano. Lett. 19, 2993–3001 (2019).
Lv, P. et al. Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy. Biomater. Sci. 9, 7392–7401 (2021).
Gutzmer, R. et al. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe. Eur. J. Dermatol. 28, 736–749 (2018).
Hom, V., Karonis, E., Sigidi, T. & Cawley, K. Development of a nursing policy for the administration of an oncolytic virus in the outpatient setting. Semin. Oncol. Nurs. 35, 150928 (2019).
Harrington, K. J. et al. A practical guide to the handling and administration of talimogene laherparepvec in Europe. Onco Targets Ther. 10, 3867–3880 (2017).
Yamaguchi, T. & Uchida, E. Oncolytic virus: regulatory aspects from quality control to clinical studies. Curr. Cancer Drug Targets 18, 202–208 (2018).
Kimball, K. J. et al. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin. Cancer Res. 16, 5277–5287 (2010).
Pol, J. G. et al. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Oncoimmunology 8, e1512329 (2019).
Lemos de Matos, A., Franco, L. S. & McFadden, G. Oncolytic viruses and the immune system: the dynamic duo. Mol. Ther. Methods Clin. Dev. 17, 349–358 (2020).
Ferguson, M. S., Lemoine, N. R. & Wang, Y. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv. Virol. 2012, 805629 (2012).
Bhatt, D. K., Chammas, R. & Daemen, T. Resistance mechanisms influencing oncolytic virotherapy, a systematic analysis. Vaccines 9, 1166 (2021).
Ajam-Hosseini, M., Akhoondi, F. & Doroudian, M. Nano based-oncolytic viruses for cancer therapy. Crit. Rev. Oncol. Hematol. 185, 103980 (2023).
Shin, D. H. et al. Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy. J. Immunother. Cancer 9, e002086 (2021).
Wakimoto, H. et al. The complement response against an oncolytic virus is species-specific in its activation pathways. Mol. Ther. 5, 275–282 (2002).
Lauer, U. M. & Beil, J. Oncolytic viruses: challenges and considerations in an evolving clinical landscape. Future Oncol. 18, 2713–2732 (2022).
Currier, M. A. et al. VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells. Mol. Ther. 21, 1014–1023 (2013).
Oh, C. M., Chon, H. J. & Kim, C. Combination immunotherapy using oncolytic virus for the treatment of advanced solid tumors. Int. J. Mol. Sci. 21, 7743 (2020).
Gujar, S. et al. Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies. Trends Immunol. 39, 209–221 (2018).
Alvarez-Breckenridge, C. A. et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat. Med. 18, 1827–1834 (2012).
Martinez-Quintanilla, J., Seah, I., Chua, M. & Shah, K. Oncolytic viruses: overcoming translational challenges. J. Clin. Investig. 129, 1407–1418 (2019).
Mendez, N. et al. Encapsulation of adenovirus serotype 5 in anionic lecithin liposomes using a bead-based immunoprecipitation technique enhances transfection efficiency. Biomaterials 35, 9554–9561 (2014).
Deng, S. et al. Development of a new hyaluronic acid based redox-responsive nanohydrogel for the encapsulation of oncolytic viruses for cancer immunotherapy. Nanomaterials 11, 144 (2021).
Wang, Y. et al. Liposome encapsulation of oncolytic virus M1 to reduce immunogenicity and immune clearance in vivo. Mol. Pharm. 16, 779–785 (2019).
Ruano, D. et al. First-in-human, first-in-child trial of autologous MSCs carrying the oncolytic virus icovir-5 in patients with advanced tumors. Mol. Ther. 28, 1033–1042 (2020).
Roberts, D. M. et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441, 239–243 (2006).
Teijaro, J. R. Pleiotropic roles of type 1 interferons in antiviral immune responses. Adv. Immunol. 132, 135–158 (2016).
Kim, Y. et al. Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy. Proc. Natl. Acad. Sci. USA 115, 4927–4932 (2018).
Meliani, A. et al. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat. Commun. 9, 4098 (2018).
Sobhanimonfared, F., Bamdad, T., Sadigh, Z. A. & Choobin, H. Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy. Microb. Pathog. 140, 103957 (2020).
Nishio, N. et al. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res. 74, 5195–5205 (2014).
Lawler, S. E., Speranza, M. C., Cho, C. F. & Chiocca, E. A. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 3, 841–849 (2017).
Ungerechts, G. et al. Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. Mol. Ther. Methods Clin. Dev. 3, 16018 (2016).
Gaudreau, P. O. et al. Neoadjuvant chemotherapy increases cytotoxic T cell, tissue resident memory T cell, and B cell infiltration in resectable NSCLC. J. Thorac. Oncol. 16, 127–139 (2021).
Husain, S. R. et al. Gene therapy for cancer: regulatory considerations for approval. Cancer Gene Ther. 22, 554–563 (2015).
Menotti, L. & Vannini, A. Oncolytic viruses in the era of omics, computational technologies, and modeling: thesis, antithesis, and synthesis. Int. J. Mol. Sci. 24, 17378 (2023).
Patel, S. K., George, B. & Rai, V. Artificial intelligence to decode cancer mechanism: beyond patient stratification for precision oncology. Front. Pharmacol. 11, 1177 (2020).
McBride, A. A. The promise of proteomics in the study of oncogenic viruses *. Mol. Cell Proteom. 16, S65–S74 (2017).
Moerdyk-Schauwecker, M. et al. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology 436, 221–234 (2013).
White, K. et al. New hints towards a precision medicine strategy for IDH wild-type glioblastoma. Ann. Oncol. 31, 1679–1692 (2020).
Keyl, P. et al. Patient-level proteomic network prediction by explainable artificial intelligence. npj Precis. Onc. 6, 35 (2022).
Shen, Y. et al. Oncolytic virus VG161 in refractory hepatocellular carcinoma. Nature 641, 503–511 (2025).
Murdaugh, R. L. & Anastas, J. N. Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma. Front. Pharmacol. 14, 1002296 (2023).
Ali, M. & Aittokallio, T. Machine learning and feature selection for drug response prediction in precision oncology applications. Biophys. Rev. 11, 31–39 (2019).
Hegde, P. S. & Chen, D. S. Top 10 challenges in cancer immunotherapy. Immunity 52, 17–35 (2020).
Chen, L. et al. Putting Proteomics Into Immunotherapy for glioblastoma. Front. Immunol. 12, 593255 (2021).
Swift, S. L. & Stojdl, D. F. Big data offers novel insights for oncolytic virus immunotherapy. Viruses. 8, 45 (2016).
Cirillo, D., Nunez-Carpintero, I. & Valencia, A. Artificial intelligence in cancer research: learning at different levels of data granularity. Mol. Oncol. 15, 817–829 (2021).
Erhart, F. et al. Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors. NPJ Vaccines 5, 5 (2020).
Benesch, M. G. K., Cherkassky, L. & Nurkin, S. J. Multi-omic analysis: a possible platform toward personalized and adaptable cancer treatment. Ann. Surg. Oncol. 31, 4831–4833 (2024).
Carrera, C., Potrony, M. & Puig, S. Sex as a predictor of response to cancer immunotherapy. Lancet Oncol. 19, e375 (2018).
Jang, S. R. et al. Association between sex and immune checkpoint inhibitor outcomes for patients with melanoma. JAMA Netw. Open. 4, e2136823 (2021).
White, J. et al. The integration of sex and gender considerations into biomedical research: lessons from international funding agencies. J. Clin. Endocrinol. Metab. 106, 3034–3048 (2021).
Madala, S. et al. Gender differences and their effects on survival outcomes in lung cancer patients treated with PD-1/PD-L1 checkpoint inhibitors: a systematic review and meta-analysis. Clin. Oncol. (R. Coll. Radio.) 34, 799–809 (2022).
Russell, S. J., Peng, K. W. & Bell, J. C. Oncolytic virotherapy. Nat. Biotechnol. 30, 658–670 (2012).
Toropko, M., Chuvpilo, S. & Karabelsky, A. miRNA-mediated mechanisms in the generation of effective and safe oncolytic viruses. Pharmaceutics 16, 986 (2024).
Raimondi, G. et al. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses. EBioMedicine 56, 102786 (2020).
Vienne, M. et al. Minute virus of mice shows oncolytic activity against pancreatic cancer cells exhibiting a mesenchymal phenotype. Mol. Ther. Oncol. 32, 200780 (2024).
Berg, D. R. et al. In vitro and in silico multidimensional modeling of oncolytic tumor virotherapy dynamics. PLoS Comput. Biol. 15, e1006773 (2019).
Lopez-Munoz, A. D., Rastrojo, A., Martin, R. & Alcami, A. High-throughput engineering of cytoplasmic- and nuclear-replicating large dsDNA viruses by CRISPR/Cas9. J. Gen. Virol. 103, 001797 (2022).
Nguyen, C., Ibe-Enwo, A. & Slack, J. A Baculovirus expression vector derived entirely from non-templated, chemically synthesized DNA parts. Viruses. 15, 1981 (2023).
Gujar, S. et al. Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy. Nat. Protoc. 19, 2540–2570 (2024).
Kim, Y. et al. Immune checkpoint blockade augments changes within oncolytic virus-induced cancer MHC-I peptidome, creating novel antitumor CD8 T cell reactivities. Mol. Cell. Proteomics. 21, 100182 (2022).
Zhu, Z. et al. Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. Mol. Cancer 21, 196 (2022).
Kondylis, P., Schlicksup, C. J., Zlotnick, A. & Jacobson, S. C. Analytical techniques to characterize the structure, properties, and assembly of virus capsids. Anal. Chem. 91, 622–636 (2019).
Zhang, X. et al. Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer. Front. Pharmacol. 14, 1130937 (2023).
Xiao, Y. et al. Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer. Clin. Cancer Res. 25, 5002–5014 (2019).
Bhat, R. & Rommelaere, J. Emerging role of natural killer cells in oncolytic virotherapy. Immunotargets Ther. 4, 65–77 (2015).
Tiriac, H., Plenker, D., Baker, L. A. & Tuveson, D. A. Organoid models for translational pancreatic cancer research. Curr. Opin. Genet. Dev. 54, 7–11 (2019).
Wang, T. et al. Accuracy of using a patient-derived tumor organoid culture model to predict the response to chemotherapy regimens in stage IV colorectal cancer: a blinded study. Dis. Colon Rectum 64, 833–850 (2021).
Driehuis, E. et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc. Natl. Acad. Sci. USA 116, 26580–26590 (2019).
Alemzadeh, E. et al. Circulating tumor cells and circulating tumor DNA in breast cancer diagnosis and monitoring. Oncol. Res. 31, 667–675 (2023).
Zhao, J. et al. Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer. Mol. Ther. 33, 703–722 (2025).
Chen, L. et al. Progress in oncolytic viruses modified with nanomaterials for intravenous application. Cancer Biol. Med. 20, 830–855 (2023).
Li, Y. et al. Oncolytic virus-like nanoparticles for tumor-specific gene delivery. Adv. Funct. Mater. 34, 2314898 (2024).
Ong, H. T. et al. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J. Hepatol. 59, 999–1006 (2013).
Kwan, A. et al. Macrophage delivered HSV1716 is active against triple negative breast cancer. Future Pharm. 2, 444–459 (2022).
West, E. J. et al. A phase I clinical trial of intrahepatic artery delivery of TG6002 in combination with oral 5-fluorocytosine in patients with liver-dominant metastatic colorectal cancer. Clin. Cancer Res. 31, 1243–1256 (2025).
Langfield, K. K., Walker, H. J., Gregory, L. C. & Federspiel, M. J. Manufacture of measles viruses. Methods Mol. Biol. 737, 345–366 (2011).
Park, J. S. et al. PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma. Cancer Cell Int. 24, 50 (2024).
Zhang, H. et al. The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient. Cancer Gene Ther. 31, 1412–1426 (2024).
Xu, M. Y. et al. Enhanced cellular therapy: revolutionizing adoptive cellular therapy. Exp. Hematol. Oncol. 13, 47 (2024).